Cell and Gene Therapy Research and Development Solutions


The recent success of cell and gene therapies has paved the way for the next generation of advanced therapeutics. While challenges remain, cell and gene therapy research is seeing a transformational shift in the way that novel modalities, such as CAR-T, CRISPR, and vectors, are developed and delivered.

Advances in gene and cell therapy include customized options where the delivery vehicle aims to correct the monogenic aberration using in vivo gene editing approaches or harness the immune system at the cellular level using ex vivo approaches.

Our integrated cell and gene therapy workflows support precise gene editing, accurate cell analysis, optimization of AAV and lentiviral vector development, and manufacturing to improve the specificity, efficacy, and safety of cell and gene delivery.

Our solutions range from functional genomics, payload design, and vector optimization to characterization, automation, and process development. By partnering together, we can help you achieve your cell and gene therapy research, development, and manufacturing goals.


For research use only. Not for use in diagnostic procedures.

Gene Therapy

Optimize Your Gene Therapy Workflows​

Gene editing technologies have shown to optimize functional genomics, genetic screening, target identification and nucleotide payload development to elevate gene therapy research. ​

In vivo gene editing uses a delivery vehicle such as a virus, for example an adeno-associated virus (AAV), or a non-viral nanoparticle which can target the gene of interest to the disease-associated tissue or organ. ​

We offer enablement and transformative solutions for your gene therapy discovery, development, and manufacturing processes: ​ ​

  • Improve your CRISPR gene editing workflows​
  • Design and characterize your delivery vector and payload cassette ​
  • Monitor the safety and efficacy of the biotherapeutic​
  • Evaluate and document your Critical Quality Attributes (CQAs)


Cell Therapy

Elevate Your Cell Therapy Programs​

Depending on availability, immunocompatibility, and sample source, cell-based therapies can be segmented into two categories: autologous and allogenic. ​

Autologous therapies are customized to an individual patient’s needs, in which cells are enriched, modified, and injected back into the same individual to elicit a desired immunotherapeutic response. ​

In allogeneic cell-based therapies, cells or tissue (e.g., bone marrow, adipose fat) from unrelated donors are banked in large batches using Good Manufacturing Practices (GMP) to treat larger patient populations.​

We offer enablement and transformative cellular therapy products for your discovery, development, and scale up processes: ​ ​

  • Accurately count and characterize both patient or donor-derived cells ​
  • Enrich, expand, and engineer your desired cells for CAR-T programs​
  • Establish well-defined immunoassay protocols to measure cell signaling and protein binding activity​
  • Evaluate and document your Critical Quality Attributes (CQAs)

Leverage Our Expertise

Explore Our Cell and Gene Therapy Solutions

More great content

Request More Information